Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia | Zendy

J C Engle | Zendy; Patti W. Lifland | Zendy; Charles J. Schleupner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia

Author(s) -

J C Engle,

Patti W. Lifland,

Charles J. Schleupner

Publication year - 1985

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.28.1.146

Subject(s) - ceftazidime , cefamandole , streptococcus pneumoniae , haemophilus influenzae , pneumonia , microbiology and biotechnology , medicine , cephalosporin , microgram , streptococcus , antibiotics , chemistry , biology , pseudomonas aeruginosa , bacteria , in vitro , biochemistry , genetics

Ceftazidime and cefamandole were compared in the treatment of pneumonia. The median MIC of ceftazidime for all Streptococcus pneumoniae (n = 17) and Haemophilus influenzae (n = 10) isolates was 0.125 microgram/ml. All other isolates were inhibited by less than 0.5 microgram of ceftazidime per ml, with the exception of a group B streptococcus (MIC = 4 micrograms/ml). Satisfactory clinical responses were observed in 91% (20 of 22) of cefamandole-treated patients and 85% (17 of 20) of ceftazidime-treated patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research